Recommended Topic Related To:

Betagan

"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...

Betagan

Indications
Dosage
How Supplied

INDICATIONS

BETAGAN® (levobunolol) ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended starting dose is one to two drops of BETAGAN® (levobunolol) ophthalmic solution 0.5% in the affected eye(s) once a day. Typical dosing with BETAGAN® (levobunolol) 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled glaucoma, BETAGAN® (levobunolol) 0.5% can be administered b.i.d. As with any new medication, careful monitoring of patients is advised. Dosages above one drop of BETAGAN® (levobunolol) 0.5% b.i.d. are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrin and/or epinephrine, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.

HOW SUPPLIED

BETAGAN® (levobunolol hydrochloride ophthalmic solution USP) Liquifilm® sterile ophthalmic solution is supplied in white opaque plastic dropper bottles as follows:

BETAGAN 0.25%: C Cap® Compliance Cap B.I.D. (twice daily)
  5 mL--NDC 11980-469-25 10 mL--NDC 11980-469-20
BETAGAN 0.5%: Standard Cap C Cap® Compliance Cap C CAP® Compliance Cap
2 mL--NDC 11980-252-02 Q.D.(once daily) B.I.D. (twice daily)
  5 mL--NDC 11980-252-65 5 mL--NDC 11980-252-25
  10 mL--NDC 11980-252-60 10 mL--NDC 11980-252-20
  15 mL--NDC 11980-252-61 15 mL--NDC 11980-252-21

NOTE: Protect from light. Store at 15°-30°C (59°-86°F).

Allergan Inc, Irvine, Califomia 29612, U.S.A. FDA rev date: 4/12/2002

Last reviewed on RxList: 10/20/2008
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.